secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2026-09-21T13:05:27+00:00
Accession:  0001601830-26-000112
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion amends Tempus master agreement, grants RNA model license for $12M
---------------------------------------------------------------------------

- Amendment extends Master Agreement term to six years, eliminates termination-for-convenience clause.
- Annual License Fees for years 3-5 revised to $14M each, with at least $4M cash, rest in stock/cash.
- Recursion grants Tempus non-exclusive oncology-only license to TxFM RNA model for 2 years.
- Tempus pays $12M total license fee in two $6M installments; first on execution, second at one-year.
- Tempus provides Recursion access to de-identified pathology records with linked clinical data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000112/0001601830-26-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000112/rxrx-20260915.htm
  HTML page:      https://secwatch.observer/filing/0001601830-26-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer